Skip to content
Vedanta Biosciences enrolls first patient in pivotal phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile Infection
We use cookies to ensure that we give you the best experience on our website. By clicking “Ok”, you consent to the use of all cookies.Ok
Toggle navigation